Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Resverlogix ( (TSE:RVX) ) has provided an update.
Resverlogix Corp. has appointed Bradley Glass, J.D., to its board of directors, bringing his extensive legal and business experience to the company. This strategic move aligns with Resverlogix’s and Hepalink’s shared goal of advancing the development of apabetalone, their leading epigenetic candidate, for treating cardiovascular disease and other chronic conditions. The appointment is expected to enhance the company’s strategic objectives and strengthen its position in the biotechnology industry.
More about Resverlogix
Founded in 2001, Resverlogix is a Calgary-based late-stage biotechnology company specializing in epigenetics, aiming to develop first-in-class therapies for chronic diseases. The company focuses on regulating disease-causing genes to improve patients’ lives, particularly in treating cardiovascular disease, associated comorbidities, and post COVID-19 conditions. Resverlogix collaborates with EVERSANA for the commercialization of its lead candidate, apabetalone, in Canada and the United States.
Average Trading Volume: 65,846
Technical Sentiment Signal: Hold
Current Market Cap: C$29.56M
See more data about RVX stock on TipRanks’ Stock Analysis page.